Treatment Of Osteoarthritis With Procollagen Galactosyl Transferase 2 (COLGALT2) Inhibitors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJonas Bovijn, Peter Dornbos, Luca Andrea Lotta, Jose Raya Garcia del Olmo, Benjamin Geraghty, Jonathan Marchini, Aris Baras, Mary Haas
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to the treatment of subjects having osteoarthritis or at risk of developing osteoarthritis by administering a Procollagen Galactosyl Transferase 2 (COLGALT2) inhibitor to the subject.
Claims22
A method of treating a subject having osteoarthritis or at risk of developing osteoarthritis, the method comprising administering a Procollagen Galactosyl Transferase 2 (COLGALT2) inhibitor to the subject.
A method of treating a subject having osteoarthritis or at risk of developing osteoarthritis by administering an osteoarthritis therapeutic agent or osteoarthritis therapy, the method comprising:
- determining or having determined whether the subject has a Procollagen Galactosyl Transferase 2 (COLGALT2) variant nucleic acid molecule, by:
- obtaining or having obtained a biological sample from the subject;
- and
- performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising a COLGALT2 variant nucleic acid molecule;
- and
- administering or continuing to administer the osteoarthritis therapeutic agent in an amount that is the same as or less than a standard dosage amount or osteoarthritis therapy, and/or a COLGALT2 inhibitor to a subject that is COLGALT2 reference;
- administering or continuing to administer the osteoarthritis therapeutic agent in an amount that is the same as or less than a standard dosage amount or osteoarthritis therapy, and/or a COLGALT2 inhibitor to a subject that is heterozygous for the COLGALT2 variant nucleic acid molecule;
- or
- administering or continuing to administer the osteoarthritis therapeutic agent in a standard dosage amount or osteoarthritis therapy to a subject that is homozygous for the COLGALT2 variant nucleic acid molecule;
- wherein the presence of the COLGALT2 variant nucleic acid molecule indicates the subject has a decreased risk of developing osteoarthritis.
A method of identifying a subject having an increased risk of developing osteoarthritis, the method comprising:
- determining or having determined the presence or absence of a Procollagen Galactosyl Transferase 2 (COLGALT2) variant nucleic acid molecule in a biological sample obtained from the subject;
- wherein:
- when the subject is COLGALT2 reference, then the subject has an increased risk of developing osteoarthritis;
- and
- when the subject is heterozygous or homozygous for the COLGALT2 variant nucleic acid molecule, then the subject has a decreased risk of developing osteoarthritis.
22-41. (canceled)
Dependencies are inferred from the claim text.